| [1] |
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2024, 45(36):3314-3414.
|
| [2] |
Schnabel RB, Yin X, Gona P, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study[J]. Lancet, 2015, 386(9989):154-162.
|
| [3] |
Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries[J]. Eur Heart J, 2016, 37(31):2478-2487.
|
| [4] |
Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial[J]. JAMA, 2019, 321(13):1275-1285.
|
| [5] |
Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial[J]. J Am Coll Cardiol, 2020, 75(25):3105-3118.
|
| [6] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [J]. Eur Heart J, 2021, 42(5): 373-498.
|
| [7] |
Chung MK, Refaat M, Shen WK, et al. Atrial fibrillation: JACC council perspectives[J]. J Am Coll Cardiol, 2020, 75(14):1689-1713.
|
| [8] |
Parameswaran R, Al-Kaisey AM, Kalman JM. Catheter ablation for atrial fibrillation: current indications and evolving technologies[J]. Nat Rev Cardiol, 2021, 18(3):210-225.
|
| [9] |
Apiyasawat S, Kornbongkotmas S, Chichareon P, et al. Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry[J]. J Arrhythm, 2021, 37(6):1434-1442.
|
| [10] |
Nabauer M, Oeff M, Gerth A, et al. Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET) [J]. Europace, 2021, 23(12): 1903-1912.
|
| [11] |
Rohr S. Arrhythmogenic implications of fibroblast-myocyte interactions[J]. Circ Arrhythm Electrophysiol, 2012, 5(2):442-452.
|
| [12] |
Wilber DJ. Fibroblasts, focal triggers, and persistent atrial fibrillation: is there a connection?[J]. Circ Arrhythm Electrophysiol, 2012, 5(2):249-251.
|
| [13] |
Platonov PG, Mitrofanova LB, Orshanskaya V, et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age [J]. J Am Coll Cardiol, 2011, 58(21): 2225-2232.
|
| [14] |
Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias [J]. Pacing Clin Electrophysiol, 1997, 20(2 Pt 2): 397-413.
|
| [15] |
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-2962.
|
| [16] |
Mahnkopf C, Badger TJ, Burgon NS, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation[J]. Heart Rhythm, 2010, 7(10):1475-1481.
|
| [17] |
Santangeli P, Zado ES, Hutchinson MD, et al. Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation[J]. Heart Rhythm, 2016, 13(2):374-382.
|
| [18] |
Lee SH, Tai CT, Hsieh MH, et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation[J]. J Am Coll Cardiol, 2005, 46(6):1054-1059.
|
| [19] |
Gianni C, Mohanty S, Trivedi C, et al. Novel concepts and approaches in ablation of atrial fibrillation: the role of non-pulmonary vein triggers[J]. Europace, 2018, 20(10):1566-1576.
|
| [20] |
Chen SA, Tai CT. Catheter ablation of atrial fibrillation originating from the non-pulmonary vein foci[J]. J Cardiovasc Electrophysiol, 2005, 16(2):229-232.
|
| [21] |
Kim KH, Mohanty S, Mohanty P, et al. Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy[J]. J Interv Card Electrophysiol, 2017, 49(2):111-117.
|
| [22] |
Lim HS, Hocini M, Dubois R, et al. Complexity and distribution of drivers in relation to duration of persistent atrial fibrillation[J]. J Am Coll Cardiol, 2017, 69(10):1257-1269.
|
| [23] |
Sugumar H, Thomas SP, Prabhu S, et al. How to perform posterior wall isolation in catheter ablation for atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2018, 29(2):345-352.
|
| [24] |
Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med, 2015, 372(19):1812-1822.
|
| [25] |
Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate[J]. J Am Coll Cardiol, 2004, 43(11):2044-2053.
|
| [26] |
Tan HW, Wang XH, Shi HF, et al. Left atrial wall thickness: anatomic aspects relevant to catheter ablation of atrial fibrillation[J]. Chin Med J (Engl), 2012, 125(1):12-15.
|
| [27] |
Wolf M, El Haddad M, Fedida J, et al. Evaluation of left atrial linear ablation using contiguous and optimized radiofrequency lesions: the ALINE study[J]. Europace, 2018, 20(FI_3):f401-f409.
|
| [28] |
Chieng D, Sugumar H, Ling LH, et al. Catheter ablation for persistent atrial fibrillation: a multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - the CAPLA study[J]. Am Heart J, 2022, 243:210-220.
|
| [29] |
Sang C, Liu Q, Lai Y, et al. Pulmonary vein isolation with optimized linear ablation vs pulmonary vein isolation alone for persistent AF: the PROMPT-AF randomized clinical trial [J]. JAMA, 2025, 333(5): 381-389.
|
| [30] |
Valderrábano M, Chen HR, Sidhu J, et al. Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans[J]. Circ Arrhythm Electrophysiol, 2009, 2(1):50-56.
|
| [31] |
Báez-Escudero JL, Morales PF, Dave AS, et al. Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation[J]. Heart Rhythm, 2012, 9(8):1207-1215.
|
| [32] |
Nakashima T, Pambrun T, Vlachos K, et al. Impact of vein of Marshall ethanol infusion on mitral isthmus block: efficacy and durability[J]. Circ Arrhythm Electrophysiol, 2020, 13(12):e008884.
|
| [33] |
Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation[J]. Circulation, 2010, 122(2):109-118.
|
| [34] |
Romero J, Michaud GF, Avendano R, et al. Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis[J]. Europace, 2018, 20(8):1268-1278.
|
| [35] |
Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF trial[J]. J Am Coll Cardiol, 2016, 68(18):1929-1940.
|
| [36] |
Di Biase L, Mohanty S, Trivedi C, et al. Stroke risk in patients with atrial fibrillation undergoing electrical isolation of the left atrial appendage[J]. J Am Coll Cardiol, 2019, 74(8):1019-1028.
|
| [37] |
Rillig A, Tilz RR, Lin T, et al. Unexpectedly high incidence of stroke and left atrial appendage thrombus formation after electrical isolation of the left atrial appendage for the treatment of atrial tachyarrhythmias[J]. Circ Arrhythm Electrophysiol, 2016, 9(5):e003461.
|
| [38] |
Romero J, Gabr M, Patel K, et al. Efficacy and safety of left atrial appendage electrical isolation during catheter ablation of atrial fibrillation: an updated meta-analysis[J]. Europace, 2021, 23(2):226-237.
|
| [39] |
Romero J, Di Biase L, Mohanty S, et al. Long-term outcomes of left atrial appendage electrical isolation in patients with nonparoxysmal atrial fibrillation: a propensity score-matched analysis[J]. Circ Arrhythm Electrophysiol, 2020, 13(11):e008390.
|
| [40] |
Cutler MJ, Johnson J, Abozguia K, et al. Impact of voltage mapping to guide whether to perform ablation of the posterior wall in patients with persistent atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2016, 27(1):13-21.
|
| [41] |
Phillips KP, Romanov A, Artemenko S, et al. Combining left atrial appendage closure and catheter ablation for atrial fibrillation: 2-year outcomes from a multinational registry[J]. Europace, 2020, 22(2):225-231.
|
| [42] |
Bai R, Di Biase L, Mohanty P, et al. Proven isolation of the pulmonary vein antrum with or without left atrial posterior wall isolation in patients with persistent atrial fibrillation[J]. Heart Rhythm, 2016, 13(1):132-140.
|
| [43] |
He X, Zhou Y, Chen Y, et al. Left atrial posterior wall isolation reduces the recurrence of atrial fibrillation: a meta-analysis[J]. J Interv Card Electrophysiol, 2016, 46(3):267-274.
|
| [44] |
Kistler PM, Chieng D, Sugumar H, et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the CAPLA randomized clinical trial[J]. JAMA, 2023, 329(2):127-135.
|
| [45] |
Passman R. Catheter ablation for persistent atrial fibrillation[J]. JAMA, 2023, 329(2):125-126.
|
| [46] |
Huo Y, Gaspar T, Pohl M, et al. Prevalence and predictors of low voltage zones in the left atrium in patients with atrial fibrillation[J]. Europace, 2018, 20(6):956-962.
|
| [47] |
Turagam MK, Neuzil P, Schmidt B, et al. Impact of left atrial posterior wall ablation during pulsed-field ablation for persistent atrial fibrillation[J]. JACC Clin Electrophysiol, 2024, 10(5):900-912.
|
| [48] |
Yamaguchi T, Otsubo T, Takahashi Y, et al. Atrial structural remodeling in patients with atrial fibrillation is a diffuse fibrotic process: evidence from high-density voltage mapping and atrial biopsy[J]. J Am Heart Assoc, 2022, 11(6):e024521.
|
| [49] |
Liu W, Li S, Han B. It is necessary to re-understand the low-voltage area in atrial fibrillation patients[J]. Front Cardiovasc Med, 2022, 9:919873.
|
| [50] |
Seewöster T, Kosich F, Sommer P, et al. Prediction of low-voltage areas using modified APPLE score[J]. Europace, 2021, 23(4):575-580.
|
| [51] |
Chen H, Li C, Han B, et al. Circumferential pulmonary vein isolation with vs without additional low-voltage-area ablation in older patients with paroxysmal atrial fibrillation: a randomized clinical trial[J]. JAMA Cardiol, 2023, 8(8):765-772.
|
| [52] |
Schade A, Costello-Boerrigter L, Steinborn F, et al. Voltage-guided ablation in persistent atrial fibrillation-favorable 1-year outcome and predictors[J]. J Interv Card Electrophysiol, 2021, 62(2):249-257.
|
| [53] |
Nery PB, Alqarawi W, Nair GM, et al. Catheter ablation of low-voltage areas for persistent atrial fibrillation: procedural outcomes using high-density voltage mapping[J]. Can J Cardiol, 2020, 36(12):1956-1964.
|
| [54] |
Hwang J, Park HS, Han S, et al. Ablation of persistent atrial fibrillation based on high density voltage mapping and complex fractionated atrial electrograms: a randomized controlled trial[J]. Medicine (Baltimore), 2021, 100(31):e26702.
|
| [55] |
Huo Y, Gaspar T, Schönbauer R, et al. Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation[J]. NEJM Evid, 2022, 1(11):EVIDoa2200141.
|
| [56] |
Yang G, Zheng L, Jiang C, et al. Circumferential pulmonary vein isolation plus low-voltage area modification in persistent atrial fibrillation: the STABLE-SR-II trial[J]. JACC Clin Electrophysiol, 2022, 8(7):882-891.
|
| [57] |
Mililis P, Kariki O, Saplaouras A, et al. Radiofrequency versus cryoballoon catheter ablation in patients with persistent atrial fibrillation: a randomized trial[J]. J Cardiovasc Electrophysiol, 2023, 34(7):1523-1528.
|
| [58] |
Shi LB, Rossvoll O, Tande P, et al. Cryoballoon vs. radiofrequency catheter ablation: insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study)[J]. Europace, 2022, 24(2):226-233.
|
| [59] |
Amin AM, Nawlo A, Ibrahim AA, et al. Efficacy and safety of radiofrequency ablation versus cryoballoon ablation for persistent atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials[J]. Egypt Heart J, 2024, 76(1):89.
|
| [60] |
唐闽. 脉冲电场消融治疗心房颤动[J/OL]. 中华心脏与心律电子杂志, 2022, 10(1): 27-31.
|
| [61] |
Batista Napotnik T, Polajžer T, Miklavčič D. Cell death due to electroporation - a review[J]. Bioelectrochemistry, 2021, 141:107871.
|
| [62] |
Howard B, Haines DE, Verma A, et al. Characterization of phrenic nerve response to pulsed field ablation[J]. Circ Arrhythm Electrophysiol, 2022, 15(6):e010127.
|
| [63] |
Maurhofer J, Kueffer T, Madaffari A, et al. Pulsed-field vs. cryoballoon vs. radiofrequency ablation: a propensity score matched comparison of one-year outcomes after pulmonary vein isolation in patients with paroxysmal atrial fibrillation[J]. J Interv Card Electrophysiol, 2024, 67(2):389-397.
|
| [64] |
Reddy VY, Mansour M, Calkins H, et al. Pulsed field vs conventional thermal ablation for paroxysmal atrial fibrillation: recurrent atrial arrhythmia burden[J]. J Am Coll Cardiol, 2024, 84(1):61-74.
|
| [65] |
Kueffer T, Stettler R, Maurhofer J, et al. Pulsed-field vs cryoballoon vs radiofrequency ablation: outcomes after pulmonary vein isolation in patients with persistent atrial fibrillation[J]. Heart Rhythm, 2024, 21(8):1227-1235.
|
| [66] |
Calvert P, Mills MT, Xydis P, et al. Cost, efficiency, and outcomes of pulsed field ablation vs thermal ablation for atrial fibrillation: a real-world study[J]. Heart Rhythm, 2024, 21(9):1537-1544.
|
| [67] |
Garapati SS, Lopez-Martinez H, Murthy MK, et al. Comparison of 30-day readmission and same day discharge rates in patients undergoing pulsed field versus radiofrequency ablation for atrial fibrillation: a multicenter analysis[J]. Heart Rhythm, 2025, S1547-5271(25)02667-0.
|
| [68] |
Wang J, Wang X, Liu W, et al. Efficacy, safety, and somatosensory comparison of pulsed-field ablation and thermal ablation: outcomes from a 2-year follow-up[J]. J Interv Card Electrophysiol, (2024-12-14)[2025-05-31]. Epub ahead of print.
|
| [69] |
Xuan F, Ding M, Liang M, et al. Bilirubin elevation associated with pulsed field ablation induced hemolysis in patients with paroxysmal atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2025, 36(6):1344-1351.
|
| [70] |
Mohanty S, Casella M, Compagnucci P, et al. Acute kidney injury resulting from hemoglobinuria after pulsed-field ablation in atrial fibrillation: is it preventable?[J]. JACC Clin Electrophysiol, 2024, 10(4):709-715.
|